Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of HB0056 in Adult Participants With Moderate to Severe Asthma
NCT07899996 is registered in ClinicalTrials.gov with Shanghai Huaota Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of HB0056 in Adult Participants With Moderate to Severe Asthma
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 21, 2025
- Completion date
- August 1, 2028
- Enrollment
- 160 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
HB0056
HB0056 SC injection every 2/4 weeks .
-
Placebo
Placebo
Primary endpoints
Registered primary outcome measures; 3 primary.
-
Part I(Phase Ib): AEs
Incidence of participants with adverse events
-
Part I (Phase Ib): Tss_max
The time required to reach the maximum concentration of HB0056 in the bloodstream after administration at steady state.
-
Part II (Phase II): Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Lead sponsor's other trials
Shanghai Huaota Biopharmaceutical Co., Ltd., most recent start first.
+13 more trials See the organization page
Similar trials
Same condition (Asthma) and phase, most recent start first.
+44 more trials See the condition page